2023
Victimization in schizophrenia and its relation to violence
Buchanan A, Stefanovics E, Rosenheck R. Victimization in schizophrenia and its relation to violence. Schizophrenia Research 2023, 255: 52-58. PMID: 36963231, DOI: 10.1016/j.schres.2023.03.018.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialMental health symptomsStudy entryCross-sectional designAntipsychotic treatmentEffectiveness trialSchizophrenia symptomsMultivariate analysisHealth symptomsSchizophreniaViolent behaviorSubstance useSymptomsRecent victimizationPotential causesAggressive behaviorChildhood experiencesBaselineMore incidentsCorrelatesTreatmentVictims of violenceSexual abuseClose friendsMost perpetratorsGender differences in outcomes of early intervention services for first episode psychosis
Hong S, Bennett D, Rosenheck R. Gender differences in outcomes of early intervention services for first episode psychosis. Early Intervention In Psychiatry 2023, 17: 715-723. PMID: 36623822, PMCID: PMC10329725, DOI: 10.1111/eip.13367.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsFemaleHumansMalePsychotic DisordersQuality of LifeSchizophreniaSex FactorsConceptsFirst-episode psychosisEarly intervention servicesClinical trialsEpisode psychosisInitial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) studyEarly interventionIntervention servicesRandomized clinical trialsComorbid substance useUS clinical trialsSignificant gender differencesNegative Syndrome ScaleBaseline gender differencesGender differencesSchizophrenia spectrum disordersAntipsychotic exposureUsual careBaseline characteristicsMood symptomsDepression subscalePsychotic disordersMasked evaluatorsSchizoaffective disorderSyndrome ScaleSecondary analysis
2013
Second generation antipsychotics: evolution of scientific knowledge or uncovering fraud
Rosenheck R. Second generation antipsychotics: evolution of scientific knowledge or uncovering fraud. Epidemiology And Psychiatric Sciences 2013, 22: 235-237. PMID: 23388147, PMCID: PMC8367331, DOI: 10.1017/s2045796012000662.Peer-Reviewed Original Research
2012
Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study
Zhang X, Chen D, Xiu M, Haile C, He S, Luo X, Zuo L, Rosenheck R, Kosten T, Kosten T. Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study. Psychological Medicine 2012, 43: 1651-1660. PMID: 23149169, DOI: 10.1017/s0033291712002590.Peer-Reviewed Original ResearchConceptsDrug-naive patientsFES patientsGeneral populationCognitive functionChronic schizophreniaHealthy controlsSmoking ratesFirst-episode drug-naive patientsFirst-episode schizophrenia patientsQuantity of smokingPositive symptom subscale scoresCase-control studyHigh smoking ratesSymptom subscale scoresCase-control designNegative Symptom ScaleTotal PANSSCigarette smokingFirst episodeNicotine dependenceFagerström TestPatientsPsychotic disordersSmokingSymptom Scale
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia
2007
Dr. Rosenheck and Colleagues Reply
ROSENHECK R, STROUP T, SWARTZ M, McEVOY J, DAVIS S, KEEFE R, HSIAO J, LIEBERMAN J. Dr. Rosenheck and Colleagues Reply. American Journal Of Psychiatry 2007, 164: 678-680. PMID: 17403984, DOI: 10.1176/ajp.2007.164.4.678a.Peer-Reviewed Original ResearchPractical applications of recent antipsychotic effectiveness data.
Lieberman J, Harvey P, Newcomer J, Rosenheck R. Practical applications of recent antipsychotic effectiveness data. The Journal Of Clinical Psychiatry 2007, 68: 151-62. PMID: 17284143, DOI: 10.4088/jcp.v68n0120.Peer-Reviewed Original Research
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeSpecial Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia
Perlick D, Rosenheck R, Kaczynski R, Swartz M, Cañive J, Lieberman J. Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia. Psychiatric Services 2006, 57: 1117-1125. PMID: 16870962, DOI: 10.1176/ps.2006.57.8.1117.Peer-Reviewed Original ResearchConceptsMedication side effectsQuality of lifeDaily livingService useSide effectsAcute inpatient phaseImpact of symptomsPatient problem behaviorsClinical Antipsychotic TrialsPatient's symptomsCaregiver burdenInpatient phaseAntipsychotic TrialsFamily burdenFamily caregiversCaregiver dataPatient behaviorTreatment programPatients' impairmentIncorporation of skillsSymptomsIntervention effectivenessDemographic characteristicsPrevious monthSchizophreniaSpecial Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos M, Glick I, Miller A, Hamner M, Miller D, Patel J, Tapp A, Keefe R, Rosenheck R. Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatric Services 2006, 57: 1094-1101. PMID: 16870959, DOI: 10.1176/ps.2006.57.8.1094.Peer-Reviewed Original ResearchConceptsConcomitant psychotropic medicationsPsychotropic medicationsConcomitant medication useIntervention Effectiveness (CATIE) trialOnly partial responseSecond-generation antipsychoticsBetter neurocognitive functioningClinical Antipsychotic TrialsPartial responseCATIE trialMedication useAnticholinergic drugsBaseline useMedication dataMood stabilizersCases symptomsConcomitant useEffectiveness trialAntipsychotic TrialsMedicationsNeurocognitive functioningSchizophreniaBaseline dataTrialsAntipsychoticsSpecial Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia
Chwastiak L, Rosenheck R, McEvoy J, Keefe R, Swartz M, Lieberman J. Special Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatric Services 2006, 57: 1102-1109. PMID: 16870960, DOI: 10.1176/ps.2006.57.8.1102.Peer-Reviewed Original ResearchConceptsMedical comorbiditiesMedical conditionsPsychiatric symptom severityPsychosocial functioningNeurocognitive impairmentSchizophrenia symptomsBaseline dataSymptom severityCross-sectional studyPhysical health statusSample of patientsClinical Antipsychotic TrialsPoorer neurocognitive functioningGreater depressive symptomsSevere schizophrenia symptomsSample of personsDiabetes mellitusAntipsychotic pharmacotherapyIndependent associationAntipsychotic TrialsMultivariate regression modelComorbiditiesPsychotic symptomsDepressive symptomsHealth status
2001
Impact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK M, ROSENHECK R, DESAI R, STOLAR M, RIPPER G. Impact of Clozapine Prescription on Inpatient Resource Utilization. The Journal Of Nervous And Mental Disease 2001, 189: 766-773. PMID: 11758660, DOI: 10.1097/00005053-200111000-00006.Peer-Reviewed Original ResearchConceptsInpatient resource utilizationClozapine treatmentInpatient daysComparison groupService utilization variablesMore inpatient daysClozapine prescriptionIndex dischargeRefractory schizophreniaConventional neurolepticsTypical neurolepticsClinical variablesVA databasesInpatient hospitalizationInpatient careYear treatmentUtilization variablesClozapineTreatmentNeurolepticsPatientsSchizophreniaUse of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
Leslie D, Rosenheck R. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System. Medical Care 2001, 39: 923-933. PMID: 11502950, DOI: 10.1097/00005650-200109000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAntipsychotic AgentsComorbidityDelivery of Health Care, IntegratedDiagnosis, Dual (Psychiatry)FemaleGuideline AdherenceHumansMaleMental Health ServicesMiddle AgedNational Health ProgramsOutcome and Process Assessment, Health CarePatient CompliancePolypharmacyPractice Guidelines as TopicSchizophreniaUnited StatesUnited States Department of Veterans AffairsConceptsPatient Outcomes Research TeamLarger mental health systemMultiple antipsychotic medicationsAntipsychotic medicationPORT recommendationsSchizophrenia Patient Outcomes Research TeamVeterans AffairsHealth systemTotal weekly doseTreatment of schizophreniaPrescription drug recordsMental health systemHealth care systemGeneralized estimation equationsMultiple antipsychoticsNational Health SystemOlder patientsWeekly doseNational health care systemPharmacy dataComorbid depressionTreatment recommendationsDrug recordsMedicationsPatientsThe Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia
LESLIE D, ROSENHECK R. The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2001, 189: 377-383. PMID: 11434638, DOI: 10.1097/00005053-200106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesBudgetsClozapineComorbidityDepressive DisorderDrug CostsFemaleHealth Care CostsHealth FacilitiesHumansMaleMiddle AgedOlanzapinePirenzepinePractice Patterns, Physicians'Regression AnalysisRisperidoneSchizophreniaTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAtypical antipsychotic medicationsTreatment of schizophreniaAtypical antipsychoticsAntipsychotic medicationExpensive atypical antipsychotic medicationsVeterans AffairsPrescription drug recordsGeneralized estimation equationsDrug recordsPatientsReduced likelihoodAntipsychoticsMedicationsFacility characteristicsSchizophreniaAtypicalsFinal sampleTreatmentOlanzapineRisperidoneDetecting Improvement in Quality of Life and Symptomatology in Schizophrenia
Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D, Schizophrenia D. Detecting Improvement in Quality of Life and Symptomatology in Schizophrenia. Schizophrenia Bulletin 2001, 27: 227-234. PMID: 11354590, DOI: 10.1093/oxfordjournals.schbul.a006869.Peer-Reviewed Original Research
2000
Benchmarking Treatment of Schizophrenia
ROSENHECK R, DESAI R, STEINWACHS D, LEHMAN A. Benchmarking Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2000, 188: 209-216. PMID: 10789997, DOI: 10.1097/00005053-200004000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAmbulatory CareCase ManagementCommunity Mental Health ServicesDay Care, MedicalDelivery of Health CareHealth StatusHospitalizationHospitals, VeteransHumansMaleMiddle AgedOutcome Assessment, Health CarePatient Acceptance of Health CareQuality of Health CareSchizophreniaSocial AdjustmentSocial Work, PsychiatricUnited StatesUnited States Department of Veterans AffairsConceptsNon-VA patientsTreatment of schizophreniaVeterans AffairsVA outpatientsVA patientsPsychosocial servicesQuality of careCase management servicesCross-sectional surveyHealth care systemMale patientsClinical outcomesClinical statusHospital treatmentVA careTreatment recommendationsVA inpatientDay hospitalCrisis intervention servicesPatientsOutpatientsClinical diagnosisSimilar satisfactionIntervention servicesCare systemQuality of Life in Schizophrenia: A Comparison of Instruments
Cramer J, Rosenheck R, Xu W, Thomas J, Henderson W, Schizophrenia D. Quality of Life in Schizophrenia: A Comparison of Instruments. Schizophrenia Bulletin 2000, 26: 659-666. PMID: 10993404, DOI: 10.1093/oxfordjournals.schbul.a033484.Peer-Reviewed Original ResearchConceptsHealth-related qualityClinical trialsTreatment effectsPatient-reported qualityLife InterviewGlobal clinical ratingsLife ScaleQuality of lifePatient responseModerate-high correlationClinical ratingsFunction scaleSymptom severitySchizophreniaStructured interviewsTrialsComparison of instrumentsRaters' assessmentsClozapineHaloperidolInpatientsLifeMultiple measuresSeverity
1999
Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology
Cicchetti D, Rosenheck R, Showalter D, Charney D, Cramer J. Interrater Reliability Levels of Multiple Clinical Examiners in the Evaluation of a Schizophrenic Patient: Quality of Life, Level of Functioning, and Neuropsychological Symptomatology. The Clinical Neuropsychologist 1999, 13: 157-170. PMID: 10949157, DOI: 10.1076/clin.13.2.157.1965.Peer-Reviewed Original ResearchClozapine and Suicide
Sernyak M, Hoff R, Rosenheck R. Clozapine and Suicide. Psychiatric Services 1999, 50: 116-116. PMID: 9890596, DOI: 10.1176/ps.50.1.116.Peer-Reviewed Original ResearchImpact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D, Schizophrenia T. Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal Of Psychiatry 1999, 156: 88-93. PMID: 9892302, DOI: 10.1176/ajp.156.1.88.Peer-Reviewed Original ResearchConceptsRefractory schizophreniaDeficit syndromeNegative symptomsPositive symptomsClozapine's effectVeterans Administration TrialEffects of clozapineImpact of clozapineNegative clinical symptomsProminent negative symptomsClozapine treatmentHospitalized patientsConventional medicationsClinical symptomsControl subjectsAdministration trialClinical subtypesAnalysis of covariancePatientsClozapineSyndromeSymptomsNegative syndromeSchizophreniaTime points